Roche Group posts strong sales growth in the first quarter

Group sales increase 6% at CER to 11.6 billion Swiss francs; Pharmaceuticals sales rise 7% to 9.2 billion Swiss francs, driven by cancer medicines and Tamiflu; Successful launches of Kadcyla and Perjeta strengthen HER2-positive breast cancer franchise; Diagnostics sales rise 1% to 2.4 billion Swiss francs; strong growth in Professional Diagnostics (+5%), decline in Diabetes Care (-5%); Full-year outlook confirmed
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news